Genetic markers associated with early cancer‐specific mortality following prostatectomy
Open Access
- 22 April 2013
- Vol. 119 (13), 2405-2412
- https://doi.org/10.1002/cncr.27954
Abstract
BACKGROUND This study sought to identify novel effectors and markers of localized but potentially life‐threatening prostate cancer (PCa), by evaluating chromosomal copy number alterations (CNAs) in tumors from patients who underwent prostatectomy and correlating these with clinicopathologic features and outcome. METHODS CNAs in tumor DNA samples from 125 patients in the discovery cohort who underwent prostatectomy were assayed with high‐resolution Affymetrix 6.0 single‐nucleotide polymorphism microarrays and then analyzed using the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm. RESULTS The assays revealed 20 significant regions of CNAs, 4 of them novel, and identified the target genes of 4 of the alterations. By univariate analysis, 7 CNAs were significantly associated with early PCa‐specific mortality. These included gains of chromosomal regions that contain the genes MYC, ADAR, or TPD52 and losses of sequences that incorporate SERPINB5, USP10, PTEN, or TP53. On multivariate analysis, only the CNAs of PTEN (phosphatase and tensin homolog) and MYC (v‐myc myelocytomatosis viral oncogene homolog) contributed additional prognostic information independent of that provided by pathologic stage, Gleason score, and initial prostate‐specific antigen level. Patients whose tumors had alterations of both genes had a markedly elevated risk of PCa‐specific mortality (odds ratio = 53; 95% CI = 6.92‐405, P = 1 × 10−4). Analyses of 333 tumors from 3 additional distinct patient cohorts confirmed the relationship between CNAs of PTEN and MYC and lethal PCa. CONCLUSIONS This study identified new CNAs and genes that likely contribute to the pathogenesis of localized PCa and suggests that patients whose tumors have acquired CNAs of PTEN, MYC, or both have an increased risk of early PCa‐specific mortality. Cancer 2013;119:2405‐2412. © 2013 American Cancer Society.Keywords
Funding Information
- National Institutes of Health (CA106523, CA95052, and CA105055, CA133066, and CA135008)
- Department of Defense (PC051264)
This publication has 27 references indexed in Scilit:
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 StudyJournal of Clinical Oncology, 2011
- The genomic complexity of primary human prostate cancerNature, 2011
- Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancerCancer, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerNature Medicine, 2009
- Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to gliomaProceedings of the National Academy of Sciences of the United States of America, 2007
- FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 2007